1. The FDA approved Johnson & Johnson’s psoriasis drug Tremfya (guselkumab). J&J used a Priority Review voucher to expedite the review of the drug. (Endpoints News)
2. A class of cancer drugs known as PARP inhibitors are not cost-effective, according to cost-effectiveness watchdog ICER. Tesaro’s Zejula, for instance, would need to be discounted between 60% and 90% to achieve cost-effectiveness thresholds, ICER researchers said. (FiercePharma)
3. Newron is preparing for the U.S. launch of Xadago, the first new drug approved by the FDA in 10 years to treat Parkinson’s disease. The drug treats Parkinson’s disease patients with motor fluctuations. (BioPharmaDive)
4. The Department of Justice charged 400 people with allegations of healthcare fraud. This includes healthcare providers who were reportedly unlawfully prescribing opioids, officials said. (WaPo)
5. Alphabet’s life-science outfit Verily is releasing mosquitoes — which carry a form of bacteria that sterilize their offspring — as a way to combat the Zika virus. Verily plans to release a million mosquitoes per week through the end of 2017. (Wired)
